Antengene (HKSE:06996) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06996 Antengene Corp Ltd HKSE:06996
40 GF Score
Price HK$4.09
GF Value HK$1.45
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Antengene FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:06996
40GF Score
Antengene Corp Ltd HKSE:06996
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Antengene (HKSE:06996) Overvalued in 2026?

Based on GuruFocus' analysis, Antengene stock appears to be overvalued. The current stock price of HK$4.09 is trading 182.1% above its estimated GF Value™ of HK$1.45. GuruFocus considers Antengene to be Significantly Overvalued.

Key valuation signals for HKSE:06996:

  • FFO:
  • GF Value™: HK$1.45 vs. price of HK$4.09 (182.1% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the HKSE:06996 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Antengene Business Description

Address 1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically, it operates in the Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
40GF Score

Get the complete analysis for HKSE:06996

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.09
Price
HK$1.45
GF Value